Wednesday, August 24, 2016 9:32:38 AM
NEWS! New Viritron Patent Filed with USPTO
The company recently filed a new Viritron patent.
Viritron VPN is a new biopharmaceutical aimed at the
bacteria that causes Pneumonia.
http://www.otcmarkets.com/stock/NTCHF/news/N1-Technologies-Patents-VIRITRON-VPN-Pneumonia-Treatment?id=139141&b=y
N1 Technologies moving forward with leading lab
The company announcing it is working with a leading Biophage
research lab, Phage Consultants located in Poland. Both
companies to team up on the research and development of
the Viritron VDX and Viritron VPN biopharmaceuticals.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM